Aerovate Therapeutics, Inc.
INHALABLE FORMULATIONS FOR KINASE INHIBITION

Last updated:

Abstract:

The invention relates to inhalable formulations configured to inhibit target combinations of kinases for the treatment of cardiovascular and pulmonary diseases such as pulmonary arterial hypertension (PAH).

Status:
Application
Type:

Utility

Filling date:

14 May 2020

Issue date:

19 Nov 2020